Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 11/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226685 | 0.99 | GBA1 (0.42) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL2229497 | 0.93 | HTT (0.46) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL14688282 | 0.93 | HTT (0.45) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL2363690 | 0.91 | HTT (0.46) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL14688368 | 0.89 | HTT (0.47) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL14688767 | 0.87 | BACE1 (0.37) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL2226638 | 0.85 | CYP46A1 (0.36) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL2282556 | 0.85 | HTT (0.44) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL14688598 | 0.85 | HTT (0.44) | GBA1HTTMEN1POLBKMT2A | |
| SCHEMBL14688509 | 0.85 | HTT (0.43) | GBA1HTTMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-02-14 | — | — | US | claimed |
| WO-2011090911-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-07-28 | — | — | WO | claimed |
| EP-2526092-B1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APH1B | GBA1 149/4885HTT 2538/4885MEN1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.